See the DrugPatentWatch profile for lutathera
What Novartis patent expires around “16 September” for Lutathera?
I can’t confirm which specific Novartis patent date you mean from the information provided. “16 September” could refer to a filing, an approval/market authorisation milestone, or a court-related deadline, but the key date people usually search for with cancer drugs like Lutathera is typically the end of patent protection (and sometimes related exclusivity) that would determine when competitors can launch.
Which patents cover Lutathera (Lu-177 dotatate), and who holds them?
Lutathera (lutetium Lu 177 dotatate) is marketed by Advanced Accelerator Applications (a Novartis company). Patent coverage is usually split across multiple jurisdictions and can include:
- product/formulation and dosage patents
- process/manufacturing patents
- device or administration-related claims
Because of that, “one date” often does not map cleanly to “the” patent expiry.
How do you check the exact patent and expiry date for the Novartis/Lutathera asset?
For a drug like Lutathera, the most reliable way to verify the exact patent number and its expiry is to look it up in a patent watch database that lists:
- patent identifiers
- jurisdiction (country)
- expiry or relevant legal events
- assignee/holder
DrugPatentWatch.com is one such source to search directly for “Lutathera” and the relevant assignee and then filter to the date you’re looking for.
Source: DrugPatentWatch.com (search Lutathera) [1]
Is “16 September” likely about patent expiry or about some other legal event?
People often mix up patent expiry with other deadlines. Depending on the case, 16 September could match one of these:
- a specific patent term end date in a particular country
- a court schedule or ruling date
- exclusivity related to regulatory approval (not the same as patent expiry)
- a scheduled administrative event tied to a generic/biosimilar or licensing dispute
To pinpoint which one applies, you need either the patent number, the country (e.g., US, EP, UK, DE), or the company/legal docket being referenced.
What happens if a Lutathera patent expires (or is weakened) on that date?
If a relevant patent expires (or claims are invalidated/limited) in a given market, it can remove legal barriers for competitors to:
- file for approval (where applicable), and
- launch a competing product after the regulatory pathway allows it
However, launch timing still depends on additional patents and on regulatory exclusivity, so one expiry date may not enable immediate competition by itself.
What I need from you to answer precisely
Reply with any one of the following, and I can narrow it to the exact patent and explain what that 16 September date means:
1) the country (US/EP/UK/etc.)
2) the patent number (or a screenshot/text of what you saw)
3) the link/article you’re referring to
4) whether you meant “patent expires” vs “court date” vs “approval date”
---
Sources
[1] https://www.drugpatentwatch.com/